Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hodgkin Disease 1Dendritic Cell Sarcoma, Interdigitating 1Burkitt Lymphoma 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 41fludarabine phosphate 37Mycophenolic Acid 28Cyclosporine 28Antilymphocyte Serum 27Peripheral Blood Stem Cell Transplantation 24Radiotherapy 23Busulfan 23Whole-Body Irradiation 22Filgrastim 22Methylprednisolone 17Tacrolimus 16Cord Blood Stem Cell Transplantation 16Melphalan 15Methotrexate 13Etoposide 8fludarabine 5Thiotepa 4Therapeutics 4Sirolimus 4Granulocyte Colony-Stimulating Factor 4Cytarabine 4sargramostim 3Flow Cytometry 3Alemtuzumab 3thymoglobulin 2aldesleukin 2Voriconazole 2Psychiatric Rehabilitation 2Prednisone 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Dendritic Cell Sarcoma, Interdigitating × Triamcinolone × Myeloid × Clear all
NCT03674411 2026-01-06

Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy

Masonic Cancer Center, University of Minnesota

Phase 2 Active not recruiting
22 enrolled 19 charts
Classical hematologyLymphoidMyeloidOther hematologic neoplasmSarcoma

Anemia, Refractory, with Excess of Blasts, Burkitt Lymphoma, Hodgkin Disease, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡